SpringTide Ventures Closes $65 Million Fund and Expands Healthcare Innovation Portfolio

SpringTide Ventures, a healthcare-focused venture capital firm, has recently closed its second fund at $65 million, increasing its total assets under management to over $100 million. The company, led by Austin Walters, aims to revolutionize the healthcare sector by democratizing access to health innovations.

SpringTide Ventures predominantly invests in health-focused software, hardware, and tech-enabled servicest. Notable investments from the firm include:

• GreatExpectations.io: The world’s leading data quality tooling company recently surpassed a rate of over 15 million downloads per month.
• Pathology Watch: An end-to-end dermatopathology software platform, including AI interpretation; acquired by Sonic Healthcare in January 2024 for $150 million.
• Debut Biotech: A leading cell-free biomanufacturing company that launched its own skin care product line in 2023 and raised a $20 million Series B led by L’Oreal.
• OpenLoop: An end-to-end telemedicine enablement company surpassed $100 million in annualized revenues in early 2024.

SpringTide Ventures has already made 15 investments from its second fund, with a focus on startups at the seed and Series A stages.  SpringTide Ventures also hosts biannual forums to address key healthcare issues and identify potential solutions.